Table 4 Top 10 enriched pathways in responders compared to non-responders after 7 weeks of omega-3 supplementation
Pathway maps | Ratio | P value | FDR | Gene transcripts |
|---|---|---|---|---|
Immune response: lysophosphatidic acid signaling via NF-κB | 5/53 | 0.0003 | 0.14 | ROCK2, IL6, CARD10, ROCK, TRIP6 |
Inhibition of TGF-beta signaling in lung cancer | 4/31 | 0.0003 | 0.14 | SERPINE1 (PAI1), TAK1 (MAP3K7), TGFBR3, SMAD6 |
Immune response: IL-11 signaling pathway via MEK/ERK and PI3K/AKT cascades | 5/67 | 0.0008 | 0.18 | YES1, HRAS, IL6, FYN, NCOA1 |
Activation of Cortisol production in major depressive disorder | 4/40 | 0.0009 | 0.18 | ASAH1, IL6, ABCB1, CYP11A1 |
Development: ACM2 and ACM4 activation of ERK | 4/43 | 0.001 | 0.18 | HRAS, CALD1, FYN, PLCB1 |
Development: Angiotensin II/ AGTR1 signaling via RhoA and JNK | 5/77 | 0.001 | 0.18 | ROCK2, RECK, SERPINE1 (PAI1), PLCB1, ROCK |
Transcription: Androgen Receptor nuclear signaling | 4/46 | 0.001 | 0.18 | HRAS, NCOA1, IL6, DVL3 |
Immune response: M-CSF-receptor signaling pathway | 5/81 | 0.002 | 0.19 | YES, CLB, HRAS, MSR1, FYN |
Chemotaxis: lysophosphatidic acid signaling via GPCRs | 6/129 | 0.003 | 0.21 | HRAS, ROCK, PREX1, PKN1, TRIP6, PLCB |
Development: angiotensin II/ AGTR1 signaling via p38, ERK and PI3K | 5/94 | 0.003 | 0.21 | RECK, SERPINE1 (PAI1), HRAS, IL6, FYN |